Quest Magazine

New ALS TDI Research Symposium Now Online





ALS TDI Laboratory
MDA and the ALS Therapy Development Institute began a jointly funded, $36 million ALS drug development project in 2007.

Major Pharmaceutical Company Commits to Develop Exon Skipping Drug

On Oct. 13, 2009, the multinational pharmaceutical company GlaxoSmithKline announced it will develop and commercialize the experimental “exon skipping” compound PRO051 for Duchenne muscular dystrophy (DMD).

The commitment of a major pharmaceutical company to development of a drug for DMD is very good news for families with this disease.

New ALS Care Guidelines Released

The American Academy of Neurology (AAN) released its new guidelines on patient care in amyotrophic lateral sclerosis (ALS) on Oct. 13, 2009. Several MDA-affiliated physicians were involved in their development.

Major Pharmaceutical Company Commits to Develop Exon-Skipping Drug

On Oct. 13, 2009, the multinational pharmaceutical company GlaxoSmithKline announced it will develop and commercialize the experimental “exon-skipping” compound PRO051 for Duchenne muscular dystrophy (DMD).

The commitment of a major pharmaceutical company to development of a drug for DMD is very good news for families with this disease.

New ALS Care Guidelines Released

The American Academy of Neurology (AAN) released its new guidelines on patient care in amyotrophic lateral sclerosis (ALS) on Oct. 13, 2009. Several MDA-affiliated physicians were involved in their development.

MDA Scientists Win Federal Stimulus Grants for Neuromuscular Disease Research

At least 15 Muscular Dystrophy Association research grantees, past and present, have won funding from the National Institutes of Health through the American Recovery and Revitalization Act (ARRA) to accelerate the search for treatments and cures for neuromuscular diseases.

New ALS Mouse Added to Research Toolkit

Mice carrying a mutation in the gene for the TDP43 protein that's known to cause amyotrophic lateral sclerosis (ALS) in humans have been developed by MDA-supported scientists at Washington University School of Medicine in St. Louis. The mice may provide an important new research tool in this deadly disease.

ALS DNA Tests Available

A new test panel that can detect “up to 35 percent” of the genetic flaws that can cause familial (inherited) ALS has been announced by Athena Diagnostics of Worcester, Mass.

Athena is a commercial laboratory specializing in DNA testing for neurological disorders.

ALS Registry FAQs

The federal government has released preliminary details about the new National ALS Registry, which will be launched in late 2010. A list of frequently asked questions (FAQs) about ALS and the registry can be viewed online at www.cdc.gov/als.    

ALS Registry FAQs

The federal government has released preliminary details about the new National ALS Registry, which will be launched in late 2010. A list of frequently asked questions (FAQs) about ALS and the registry can be viewed online at www.cdc.gov/als.    

Pages